Upgrade of Recommendation

Similar documents
Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD

Between Coronary Angiography and Fractional Flow Reserve

Integrated Use of IVUS and FFR for LM Stenting

Perspective of LM stenting with Current registry and Randomized Clinical Data

Unprotected LM intervention

Left Main Intervention: Where are we in 2015?

Left Main Intervention: Will it become standard of care?

LM stenting - Cypher

Important LM bifurcation studies update

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

PCI for Left Anterior Descending Artery Ostial Stenosis

Plaque Shift vs. Carina Shift Prevalence and Implication

Basics of Angiographic Interpretation Analysis of Angiography

Percutaneous Intervention of Unprotected Left Main Disease

Declaration of conflict of interest. Nothing to disclose

New Insight about FFR and IVUS MLA

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

Benefit of Performing PCI Based on FFR

OCT guidance for distal LM lesions

The MAIN-COMPARE Study

PCI vs. CABG From BARI to Syntax, Is The Game Over?

Left Main and Bifurcation Summit I. Lessons from European LM Studies

PCI for Long Coronary Lesion

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

PCI for LMCA lesions A Review of latest guidelines and relevant evidence

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Rationale for Percutaneous Revascularization ESC 2011

The SYNTAX-LE MANS Study

IVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Most Patients with Elective Left Main Disease. Farrel Hellig

FFR and intravascular imaging, which of which?

ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE

Incidence and Treatment for LM In-Stent

PCI for In-Stent Restenosis. CardioVascular Research Foundation

IVUS vs FFR Debate: IVUS-Guided PCI

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

Drug Eluting Stents: Bifurcation and Left Main Approach

DES In-stent Restenosis

Kurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Count Down to COMBAT

FFR-guided Jailed Side Branch Intervention

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore

Anatomical, physiological and clinical relevance of a side branch

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Prognostic Value of Gated Myocardial Perfusion SPECT

Fractional Flow Reserve: Review of the latest data

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Lessons learned From The National PCI Registry

PROMUS Element Experience In AMC

True Bifurcation LM Stenosis (Medina 1,1,1) With Very Extensive Calcification: CABG Or PCI?

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016

FRACTIONAL FLOW RESERVE: STANDARD OF CARE

high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy

Side Branch Occlusion

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

FFR in Multivessel Disease

Can We Safely Defer PCI. Yes, already proven

Why I try to avoid side branch dilatation

FFR Incorporating & Expanding it s use in Clinical Practice

Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation

Post PCI functional testing and imaging: case based lessons from FFR React

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials

COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil

Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.

The MAIN-COMPARE Registry

New Generation Drug- Eluting Stent in Korea

Controversies in Cardiac Surgery

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

Clinical case in perspective. Cases from Poland

PCIs on Intermediate Lesions NCDR Cath-PCI Registry

PCI for Chronic Total Occlusions

SYNTAX score before decision making! Corrado Tamburino, MD, PhD

Final Kissing Ballooning Returns? The analysis of COBIS II registry

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

IVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Abbott Vascular. PROTOCOL EXCEL Clinical Trial

Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality

Coronary stenting: the appropriate use of FFR

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

COMBAT- Revised Protocol

Fractional Flow Reserve and instantaneous wave -free Ratio. Λάμπρος Κ. Μόσιαλος Επεμβατικός Καρδιολόγος ΓΝ Παπαγεωργίου

FFR and IVUS Guided DES Implantation in Long Diffuse Lesions

ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΝΟΣΟ ΣΤΕΛΕΦΟΥΣ

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

What do the guidelines say?

The Site of Plaque Rupture in Native Coronary Arteries

Transcription:

Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea

Upgrade of Recommendation for PCI at Unprotected Left Main Stenosis Stenting is relatively more favorable for Patients with isolated ULMCA lesions or 1-vessel disease, Patients with ostial or mid ULMCA, patients with factors for high-risk CABG. CABG may be relatively more favorable for Patients with ULMCA plus multivessel disease, Distal/bifurcation ULMCA lesions, or Low surgical risk with a good chance of technical success. Circulation, 2009 NOV

Still challenging in your decision-making Treat or not? PCI vs. CABG? Lesion preparation? Stent type Stent optimization

Methods to help you make a decision in the Cath lab Angiography Intravascular ultrasound Fractional flow reserve

Angiography The first step to determine the patient s need of revascularization A basis to decide your treatment plan between stenting vs. CABG Remains a standard imaging modality during coronary stenting

Syntax score (newly developed system) Dominance Number & location of lesions takes into account the heterogeneity of coronary angiographic complexity based on the lesion s characteristics. Calcification Thrombus Bifurcation SYNTAX score Tortuosity Left Main 3 Vessel Total Occlusion Can be used to (1) predict long-term outcomes and (2) help your decision-making

SYNTAX Score Application for MAIN COMPARE registry MAIN-COMPARE Database (total 2240 patients) Retrospective collection of angiogram 1703 angiograms were collected Analysis Final Analysis for 1580 (71%) patients PCI (N=819), CABG (N=761) Kim YH et al. JACC Cardiov Int (in print)

Distribution of SYNTAX Score Non-normal distribution Frequency (#) Mean 30.9 ± 14.2 Median 30.0 IQR 19, 40 Tertiles 23, 36 K-S test p < 0.001 Score

Distribution of SYNTAX Score Comparison with the SYNTAX Trial SYNTAX score tertiles in SYNTAX Study SYNTAX score tertiles in MAIN-COMPARE 22 > 22 and 32 > 32 23 > 23 and 36 > 36

Discrimination and Calibration For Death, MI, Stroke Discrimination Model C-index (95% CI) Akaike Information Criterion Overall patients Calibration Slope of the Linear Predictor SYNTAX score 0.59 (0.55-0.64) 1993.9 1.12 EuroSCORE 0.67 (0.62-0.71) 1949.6 1.02 SYNTAX score + EuroSCORE 0.68 (0.63-0.72) 1948.5 1.00 PCI patients SYNTAX score 0.63 (0.57-0.70) 765.4 1.07 EuroSCORE 0.64 (0.56-0.72) 752.5 1.06 SYNTAX score + EuroSCORE 0.67 (0.59-0.74) 750.2 1.02 CABG patients SYNTAX score 0.53 (0.47-0.59) 1040.2 0.78 EuroSCORE 0.67 (0.61-0.73) 1010.7 0.99 SYNTAX score + EuroSCORE 0.68 (0.62-0.73) 1012.7 0.99

Discrimination and Calibration For Death, MI, Stroke, TVR Discrimination Model C-index (95% CI) Akaike Information Criterion Overall patients Calibration Slope of the Linear Predictor SYNTAX score 0.53 (0.48-0.55) 3511.0 0.93 EuroSCORE 0.57 (0.53-0.60) 3493.9 1.09 SYNTAX score + EuroSCORE 0.57 (0.53-0.60) 3495.7 1.02 PCI patients SYNTAX score 0.57 (0.52-0.61) 1874.3 1.00 EuroSCORE 0.53 (0.48-0.58) 1876.5 1.16 SYNTAX score + EuroSCORE 0.57 (0.52-0.61) 1874.6 0.97 CABG patients SYNTAX score 0.51 (0.46-0.57) 1301.3 0.89 EuroSCORE 0.64 (0.58-0.69) 1277.2 1.05 SYNTAX score + EuroSCORE 0.64 (0.58-0.69) 1279.1 1.01

Stratified According to Stent Type For Death, MI, Stroke Discrimination Model C-index (95% CI) Akaike Information Criterion Calibration Slope of the Linear Predictor PCI patients receiving BMS SYNTAX score 0.61 (0.50-0.71) 163.7 0.81 EuroSCORE 0.52 (0.36-0.69) 164.1 0.41 SYNTAX score & EuroSCORE 0.59 (0.46-0.72) 165.3 0.46 PCI patients receiving DES SYNTAX score 0.66 (0.58-0.74) 532.3 1.15 EuroSCORE 0.68 (0.60-0.77) 517.5 1.05 SYNTAX score & EuroSCORE 0.71 (0.63-0.79) 515.7 0.96

Stratified According to Stent Type For Death, MI, Stroke, TVR Discrimination Model C-index (95% CI) Akaike Information Criterion Calibration Slope of the Linear Predictor PCI patients receiving BMS SYNTAX score 0.48 (0.40-0.56) 374.9 0.34 EuroSCORE 0.53 (0.42-0.56) 373.6 1.35 SYNTAX score & EuroSCORE 0.53 (0.42-0.63) 375.5 0.59 PCI patients receiving DES SYNTAX score 0.60 (0.55-0.65) 1333.4 1.09 EuroSCORE 0.53 (0.47-0.58) 1340.1 0.88 SYNTAX score & EuroSCORE 0.60 (0.55-0.65) 1334.8 0.97

Death, MI, Stroke SYNTAX score was weakly predictive of a composite of safety endpoints, in patients undergoing PCI. However, the SYNTAX score lost the predictive ability for patients undergoing CABG. Death, MI, Stroke, TVR Neither the SYNTAX score nor the EuroSCORE showed good discriminatory power. In patients treated with DES, the predictabilities of events were improved by combination of SYNTAX score and EuroSCORE.

Serruys PW TCT 2009

IVUS Lesion assessment Selection of PCI technique Selection of appropriate device Procedural optimization Assessment of DES failures

We can treat the LM disease in a case of MLA < 6.0 mm 2 Prediction of FFR (0.75) with IVUS parameter 2.8mm 5.9mm 2 67% 50% Jasti V et al. Circulation 2004;110:2831

Plaque Characterization Lesion preparation : need of rotablation, debulking Drug : need of IIb/IIIa, aggressive antiplatelets Fibrous plaque Plaque rupture Thrombi Calcification Courtesy of Dr. Gary S. Mintz

Goal of LM Stent Area > 9 mm 2 % 100 80 60 40 20 0 Sensitivity Optimal SCA and Restenosis BMS Specificity 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0 12.5 10.1 100 80 60 40 20 0 MSA (mm 2 ) DES Sensitivity Specificity 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 8.8 Park SJ et al, Circ Cardiovasc Intervent. 2009;2:167-177

Goal of LAD & LCX Stent Area > 5 mm 2 Optimal SCA and Restenosis (%) 100 90 80 70 60 50 40 30 20 10 0 Stent CSA (mm 2 ) 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 Specificity Sensitivity Hong MK, Eur Heart J, 2006:27:1305, AMC data

Angiography and IVUS Lesion-specificspecific Single stent Two stent Ÿ Normal ostial LCX with MEDINA 1.1.0. or 1.0.0. Ÿ Small LCX with < 2.5 mm in diameter Ÿ Ostial LCX area ³ 4 mm 2 by IVUS Ÿ Diminutive LCX Ÿ Normal or focal disease in distal LCX Ÿ Diseased LCX with MEDINA 1.1.1., 1.0.1., or 0.1.1 Ÿ Large LCX with ³ 2.5 mm in diameter Ÿ Ostial LCX area < 4 mm 2 by IVUS Ÿ Diseased left dominant coronary system Ÿ Concomitant diffuse disease in distal LCX Park SJ, Kim YH. Colombo A, Issam D. Moussa et al. Textbook of Bifurcation Stenting

FFR Assessment of ischemia in LM and side branch

LM Bifurcation Treated with Cross-over Pre Post

But, LM Stenoses are rarely isolated LM ischemia cannnot be evaluated well with FFR Courtesy of B. De Bruyne, MD

Nothing is complete alone. We still need an integrated approach with clinical manifestation, angiography, IVUS and FFR in making your decision for unprotected LM stenosis. We need further researches to test the interrelationship across the diagnostic devices.